Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis

In a real-world cohort study at a tertiary IBD treatment center, Janus Kinase inhibitors (JAKi) demonstrated efficacy in treating moderate to severe active Ulcerative Colitis (UC), with 81% of patients achieving clinical remission and 63% achieving biochemical remission. The study included 52 patients, with an additional 24 patients assessed for secondary outcomes after early treatment discontinuation. Despite 60% of patients experiencing adverse events (AEs), 84% continued treatment. The most common AEs were hypercholesteremia and cold/flu-like symptoms, with 25% discontinuing treatment due to AEs. No Serious Adverse Events were reported. Tofacitinib, Filgotinib, and Upadacitinib all caused side effects in 60%, 53%, and 68% of patients, respectively. The study concluded that JAKi has an acceptable safety profile and is effective in inducing remission in UC patients.